Plerixafor (also known as AMD3100) blocks colony formation in NSCLC induced by CAF-derived CXCL12 [23], and interleukin-24 (IL-24) expression inhibits activation of the protein kinase B (AKT) downstream of the CXCL12/CXCR4 signaling pathway. This evidence concerns the gene IL24 and non-small cell lung carcinoma.